Statins and portal hypertension: a systematic review and meta-analysis of randomized controlled trials.
Rho-kinase activity
Statins
chronic liver disease
nitric oxide
portal hypertension
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
18 Sep 2023
18 Sep 2023
Historique:
received:
02
01
2023
revised:
20
07
2023
accepted:
08
08
2023
medline:
19
9
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
aheadofprint
Résumé
Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not. A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software. Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis. Treatment with statins did not decrease significantly portal hypertension.
Sections du résumé
BACKGROUND
BACKGROUND
Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not.
METHODS
METHODS
A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software.
RESULTS
RESULTS
Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis.
CONCLUSION
CONCLUSIONS
Treatment with statins did not decrease significantly portal hypertension.
Identifiants
pubmed: 37723637
pii: CMC-EPUB-134638
doi: 10.2174/0929867331666230918114451
doi:
Types de publication
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.